Drilldown: Medicines

Tea (1) · Ticagrelor (1)

''Camellia sinensis'' (formerly ''Thea sinensis'') (1) · Brilinta (1)

Caffeine plant (1) · Excitantia (1) · Plant Medicine (1) · [[:Category:Antiplatelet_agents|Antiplatelet agent]] (1) · [[:Category:Cyclopentyltriazolopyrimidines|Cyclopentyltriazolopyrimidine]] (1) · [[:Category:P2Y12_inhibitors|P2Y12 receptor inhibitor (reversible)]] (1)

None (1) · Caffeine + theophylline + L-theanine. L-theanine (an amino acid unique to tea) modulates glutamate and produces an 'alpha-wave' calming overlay on caffeine's stimulation, hence tea's reputation as a 'cleaner' stimulant than coffee. (1)

'"`UNIQ--vote-00000747-QINU`"', '"`UNIQ--vote-00000748-QINU`"' (1) · '"`UNIQ--vote-00000C8F-QINU`"', '"`UNIQ--vote-00000C90-QINU`"', '"`UNIQ--vote-00000C91-QINU`"' (1)

ACS/PCI: 180 mg PO loading dose, then 90 mg PO BID for 12 months; long-term post-MI: 60 mg BID (1) · One cup (~40–60 mg caffeine; about half of brewed coffee) (1)

60, 90 mg tablets (1) · Dried leaves, infused. Six major processings: white, green, yellow, oolong, black, pu-erh (1)

None (1) · 90 mg BID (acute year); 60 mg BID (chronic post-MI) (1)

None · Oral · IV · topical · IM · intranasal · rectal · subcutaneous · topical ophthalmic · ophthalmic · intramuscular · intravenous · transdermal · vaginal · Subcutaneous (abdomen · sublingual · thigh · inhaled · SC · intra-articular

Other values:

Search

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

12 hours (1) · 3–4 h (1)

~5 h (caffeine) (1) · ~7 hours (parent); ~9 hours (active AR-C124910XX metabolite, accounts for ~30-40% of activity)'"`UNIQ--ref-00000C92-QINU`"' (1)

None (1) · ~36% (oral)'"`UNIQ--ref-00000C93-QINU`"' (1)

None (1) · Limited data; weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for bleeding risk and against aspirin maintenance doses above 100 mg/d (reduces ticagrelor efficacy, per PLATO subgroup analysis)'"`UNIQ--ref-00000C94-QINU`"' (1)